Phase 3 Alzheimer's Disease Trial, Recruiting NCT07284472 Sponsor: Exciva GmbH Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT07284472
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged between 55 and 90 years (inclusive) who are able to move around on their own, with a walker, or with a wheelchair.
  • People who have already been diagnosed with Alzheimer's disease (AD) dementia.
  • People who are experiencing moderate to severe agitation (such as restlessness or distress) at the time of screening and have been experiencing it for at least 2 weeks before the study begins.
  • People whose agitation meets a specific definition set by an international medical organisation called the International Psychogeriatric Association (confirm with trial site).
  • People who have a caregiver who is willing and able to follow all study requirements and who spends time with the participant on at least four separate days per week for at least two hours each day.

Who may not be able to join:

  • People whose primary dementia diagnosis is a type of dementia other than Alzheimer's disease.
  • People whose agitation is caused by something other than Alzheimer's disease.
  • People who have a history of uncontrolled seizures or epilepsy.
  • People who have a serious or unstable medical condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +49 6221-6479990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Exciva GmbH
Registry
ClinicalTrials.gov
Start date
2 February 2026
Est. completion
1 January 2029

Where this trial is recruiting

🇨🇦 Canada 🇨🇿 Czechia 🇩🇪 Germany 🇮🇹 Italy 🇵🇱 Poland 🇸🇰 Slovakia 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Changes from baseline to endpoint (Week 6) in the Cohen-Mansfield Agitation Inventory - International Psychogeriatric Association (CMAI-IPA) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov